Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 384

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 4
Chunk 384
---
 purchase 4,088 shares of Common Stock at an exercise price of $0.80; (v) December 2024 and January 2025 Common Warrants to
purchase an aggregate of 12,396 shares of Common Stock at an exercise price ranging from $112.20 to $116.40, (vi) February 2025
Common Warrants to purchase an aggregate of 127,551 shares of Common Stock at an exercise price of $39.20, (vii) Pre-Funded Warrants
to purchase an aggregate of 10,787 shares of Common Stock at an exercise price of $0.002, (ix) Public Warrants and Private Placement
Warrants to purchase an aggregate of 4,596 shares of Common Stock at an exercise price of $23,000.00 per share and (x) 10,000 shares
of Series D Preferred Stock with a conversion value of approximately $10 million, convertible into shares of Common Stock at a
conversion rate of the stated value thereof divided by a current effective conversion price of $15.60.

41

Although each of the conversion price of most of the Preferred Shares
and the exercise prices of the December 2024 Common Warrants, January 2025 Common Warrants, Series A Warrants and February 2025 Common
Warrants are at or above the trading price of our Common Stock as of the date of this Quarterly Report, if such trading price increases,
such conversion prices and exercise prices will not change as a result thereof and could be below the trading price of our Common Stock
as of the date of any future conversion or exercise thereof, resulting in dilution to our stockholders. In addition, the terms of the
Series A Preferred Stock, the Series C Preferred Stock and Series D Preferred Stock contain certain penalties and adjustments to the amount
included in determination of the conversion rate following certain breaches of the Company’s obligations thereunder, including,
among other things, as a result of a failure to file or cause the SEC to declare one or more registration statements relating to the resale
of the shares of Common Stock issuable upon conversion thereof by specified deadlines, certain defaults under indebtedness of the Company
or judgments against the Company and failure to deliver shares of Common Stock upon conversion in a timely manner. For example, the penalties
and adjustments include a 25% premium added to the stated value for determining the conversion rate in connection with breaches other
than the breach of the requirement to redeem the shares of Series A